BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

70 related articles for article (PubMed ID: 8135488)

  • 1. Prognostic significance of estrogen receptor expression in ovarian cancer. Immunoreactive Score (IRS) vs. Composition Adjusted Receptor Level (CARL).
    Kieback DG; Press MF; Atkinson EN; Edwards GL; Möbus VJ; Runnebaum IB; Kreienberg R; Jones LA
    Anticancer Res; 1993; 13(6B):2489-96. PubMed ID: 8135488
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Improved prediction of survival in advanced adenocarcinoma of the ovary by immunocytochemical analysis and the composition adjusted receptor level of the estrogen receptor.
    Kieback DG; McCamant SK; Press MF; Atkinson EN; Gallager HS; Edwards CL; Hajek RA; Jones LA
    Cancer Res; 1993 Nov; 53(21):5188-92. PubMed ID: 8221656
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Prognostic value of estrogen receptor and progesterone receptor tumor expression in Danish ovarian cancer patients: from the 'MALOVA' ovarian cancer study.
    Høgdall EV; Christensen L; Høgdall CK; Blaakaer J; Gayther S; Jacobs IJ; Christensen IJ; Kjaer SK
    Oncol Rep; 2007 Nov; 18(5):1051-9. PubMed ID: 17914554
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Overexpression of epithelial macrophage colony-stimulating factor (CSF-1) and CSF-1 receptor: a poor prognostic factor in epithelial ovarian cancer, contrasted with a protective effect of stromal CSF-1.
    Chambers SK; Kacinski BM; Ivins CM; Carcangiu ML
    Clin Cancer Res; 1997 Jun; 3(6):999-1007. PubMed ID: 9815777
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Expression level of Wilms tumor 1 (WT1) protein has limited prognostic value in epithelial ovarian cancer: from the Danish "MALOVA" ovarian cancer study.
    Høgdall EV; Christensen L; Kjaer SK; Blaakaer J; Christensen IJ; Gayther S; Jacobs IJ; Høgdall CK
    Gynecol Oncol; 2007 Aug; 106(2):318-24. PubMed ID: 17540436
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Prognostic value of estrogen receptor and progesterone receptor status in young Chinese ovarian carcinoma patients.
    Yang XY; Xi MR; Yang KX; Yu H
    Gynecol Oncol; 2009 Apr; 113(1):99-104. PubMed ID: 19178934
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Steroid receptors in epithelial ovarian carcinoma: relation to clinical parameters and survival.
    Bizzi A; Codegoni AM; Landoni F; Marelli G; Marsoni S; Spina AM; Torri W; Mangioni C
    Cancer Res; 1988 Nov; 48(21):6222-6. PubMed ID: 3167868
    [TBL] [Abstract][Full Text] [Related]  

  • 8. EGFR and steroid receptors in ovarian carcinoma: comparison with prognostic parameters and outcome of patients.
    Fischer-Colbrie J; Witt A; Heinzl H; Speiser P; Czerwenka K; Sevelda P; Zeillinger R
    Anticancer Res; 1997; 17(1B):613-9. PubMed ID: 9066588
    [TBL] [Abstract][Full Text] [Related]  

  • 9. [Proliferating cell nuclear antigen (PCNA) in ovarian carcinoma and its relation to lymph node metastasis and prognosis].
    Wu X; Zhang Z; Cai S
    Zhonghua Zhong Liu Za Zhi; 1998 Jan; 20(1):68-70. PubMed ID: 10921065
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Survival impact of surgical cytoreduction in stage IV epithelial ovarian cancer.
    Bristow RE; Montz FJ; Lagasse LD; Leuchter RS; Karlan BY
    Gynecol Oncol; 1999 Mar; 72(3):278-87. PubMed ID: 10053096
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Effect of epidermal growth factor receptor expression level on survival in patients with epithelial ovarian cancer.
    Psyrri A; Kassar M; Yu Z; Bamias A; Weinberger PM; Markakis S; Kowalski D; Camp RL; Rimm DL; Dimopoulos MA
    Clin Cancer Res; 2005 Dec; 11(24 Pt 1):8637-43. PubMed ID: 16361548
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Tumor cell type can be reproducibly diagnosed and is of independent prognostic significance in patients with maximally debulked ovarian carcinoma.
    Gilks CB; Ionescu DN; Kalloger SE; Köbel M; Irving J; Clarke B; Santos J; Le N; Moravan V; Swenerton K;
    Hum Pathol; 2008 Aug; 39(8):1239-51. PubMed ID: 18602670
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Are cytosol estrogen and progestin receptors of prognostic significance in the management of epithelial ovarian cancers?
    Schwartz PE; MacLusky N; Merino MJ; Livolsi VA; Kohorn EI; Eisenfeld A
    Obstet Gynecol; 1986 Dec; 68(6):751-8. PubMed ID: 3785785
    [TBL] [Abstract][Full Text] [Related]  

  • 14. [Estrogens, cathepsin D and metastasis in cancers of the breast and ovary: invasion or proliferation?].
    Rochefort H
    C R Seances Soc Biol Fil; 1998; 192(2):241-51. PubMed ID: 9841098
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Estrogen receptor subtypes in ovarian cancer: a clinical correlation.
    Chan KK; Wei N; Liu SS; Xiao-Yun L; Cheung AN; Ngan HY
    Obstet Gynecol; 2008 Jan; 111(1):144-51. PubMed ID: 18165403
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Prognostic significance of residual disease in patients with stage IV epithelial ovarian cancer.
    Munkarah AR; Hallum AV; Morris M; Burke TW; Levenback C; Atkinson EN; Wharton JT; Gershenson DM
    Gynecol Oncol; 1997 Jan; 64(1):13-7. PubMed ID: 8995541
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Expression and prognostic significance of kallikrein-related peptidase 8 protein levels in advanced ovarian cancer by using automated quantitative analysis.
    Kountourakis P; Psyrri A; Scorilas A; Markakis S; Kowalski D; Camp RL; Diamandis EP; Dimopoulos MA
    Thromb Haemost; 2009 Mar; 101(3):541-6. PubMed ID: 19277417
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Gene expression of estrogen receptor, progesterone receptor and microtubule-associated protein Tau in high-risk early breast cancer: a quest for molecular predictors of treatment benefit in the context of a Hellenic Cooperative Oncology Group trial.
    Pentheroudakis G; Kalogeras KT; Wirtz RM; Grimani I; Zografos G; Gogas H; Stropp U; Pectasides D; Skarlos D; Hennig G; Samantas E; Bafaloukos D; Papakostas P; Kalofonos HP; Pavlidis N; Fountzilas G
    Breast Cancer Res Treat; 2009 Jul; 116(1):131-43. PubMed ID: 18668363
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Prognosis and hormone receptor status in older and younger patients with advanced-stage papillary serous ovarian carcinoma.
    Liu JF; Hirsch MS; Lee H; Matulonis UA
    Gynecol Oncol; 2009 Dec; 115(3):401-6. PubMed ID: 19796795
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Estrogen and progesterone receptor status as prognostic indicators in patients with optimally cytoreduced stage IIIc serous cystadenocarcinoma of the ovary.
    Geisler JP; Wiemann MC; Miller GA; Geisler HE
    Gynecol Oncol; 1996 Mar; 60(3):424-7. PubMed ID: 8774651
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 4.